Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $51.00 | Total: $255.00 |
| 1 | 10 | $43.20 | Total: $432.00 |
| 1 | 25 | $36.60 | Total: $915.00 |
| 1 | 50 | $31.20 | Total: $1,560.00 |
| 1 | 100 | $27.00 | Total: $2,700.00 |
Overview
PARP12TNKS12-IN-1 is a multi-target inhibitor of PARP-1, PARP-2, TNKS1, and TNKS2, with potential anti-tumor activity that induces apoptosis.
Chemical Properties
| Molecular Formula | C35H31FN6O5 |
| Molecular Weight | 634.66 |
| CAS Numbers | 2243453-32-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COC1=CC=C(NC(C2=CC=C(NC(N3CCN(CC3)C(C4=CC(CC5=NNC(C6=C5C=CC=C6)=O)=CC=C4F)=O)=O)C=C2)=O)C=C1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Xu Y, et al. Rational design, synthesis and biological evaluation of dual PARP-12 and TNKS12 inhibitors for cancer therapy. Eur J Med Chem. 2022 Jul 5;237 114417.